Gene expression data from 62 colorectal cancers
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE35896 | GEO | 2013/01/14
SECONDARY ACCESSION(S): PRJNA151957
REPOSITORIES: GEO
Similar Datasets
Project description:We stratified colorectal tumor samples using a new unsupervised, iterative method based on non-negative matrix factorization (NMF). The resulting five subtypes exhibited activation of specific signaling pathways, and significant differences in microsatellite status and tumor location. We could also align three CRC cell lines panels to these subtypes. mRNA from 62 colorectal tumor samples was hybridized to Affymetrix HGU133 Plus 2.0 expression arrays. Log2 gene expression values were calculated using RMA.
2013-01-14 | E-GEOD-35896 | biostudies-arrayexpress
Project description:We report the identification of five subtypes of myelodysplastic syndromes (MDS) identified via unsupervised classification of DNA methylation (DNAm) profiles. Bisulfite padlock probe sequencing (BSPP) was used to measure DNAm of ~500,000 unique CpGs covering 140,749 non-overlapping regulatory regions across the genome in bone marrow DNA samples from 141 patients with MDS. Application of a non-negative matrix factorization (NMF) decomposition of DNAm profiles identified five consensus clusters described by five NMF components as the most stable grouping solution.
2019-09-30 | GSE129828 | GEO
Project description:In order to identify key pathways associated with disease aggressiveness and therapeutics resistance in the most agrressive subset of PDAC, we analyzed gene expression profiling of tumor and adjacent non-tumor tissues from PDAC cases. Non-negative matrix factorization (NMF) clustering, using gene expression profile form PDAC tumors, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival. Mechanistic and functional analyses of most aggressive subset revealed a HNF1B/Clusterin Axis negatively regulate pancreatic cancer progression and potentially be useful in designing novel strategies to attenuate disease progression. Affymetrix data from from these dataset were partially earlier submited by us as GEO accession#: GSE28735 and GSE 62452. The batch effect between the different sets of data was removed using Partek Genomic Suite and this normalized data was submitted to GEO in this submission.
2022-12-01 | GSE183795 | GEO
Project description:To identify molecular subtypes of medulloblastoma we have profiled a series of 62 medulloblastoma tumors. Unsupervised hierarchical cluster analysis of these data identified 5 distinct molecular subtypes. Manuscript submitted. Title: Identification of medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Authors: Marcel Kool, Jan Koster, Jens Bunt, Nancy E. Hasselt, Arjan Lakeman, Peter van Sluis, Dirk Troost, Netteke Schouten – van Meeteren, Huib N. Caron, Alan Mršić, Bauke Ylstra, Wieslawa Grajkowska, Wolfgang Hartmann, Torsten Pietsch, David Ellison, Steven C. Clifford, Rogier Versteeg. Keywords: tumor classification
2008-09-02 | GSE10327 | GEO
Project description:To identify molecular subtypes of medulloblastoma we have profiled a series of 62 medulloblastoma tumors. Unsupervised hierarchical cluster analysis of these data identified 5 distinct molecular subtypes. Manuscript submitted. Title: Identification of medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Authors: Marcel Kool, Jan Koster, Jens Bunt, Nancy E. Hasselt, Arjan Lakeman, Peter van Sluis, Dirk Troost, Netteke Schouten â van Meeteren, Huib N. Caron, Alan MrÅ¡iÄ, Bauke Ylstra, Wieslawa Grajkowska, Wolfgang Hartmann, Torsten Pietsch, David Ellison, Steven C. Clifford, Rogier Versteeg. Keywords: tumor classification 62 human medulloblastoma samples were analzyed
2008-09-02 | E-GEOD-10327 | biostudies-arrayexpress
Project description:Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and validated by non-negative matrix factorization . BACKGROUND: Current clinical and histopathological criteria used to define lung squamous cell carcinomas (SCCs) are insufficient to predict clinical outcome. We attempted to make a clinically-useful classification based on gene expression profiling. METHODS: We used cDNA microarrays with 40386 elements to analyze the gene expression profiles of 48 surgically resected samples of lung SCC. 9 samples of lung adenocarcinoma and 30 of normal lung were also included to give a total of 87 samples analyzed. After gene filtering, the data were subjected to hierarchical clustering and consensus clustering with the non-negative matrix factorization (NMF) approach. FINDINGS: Initial analysis by hierarchical clustering allowed division of SCCs into two distinct subclasses. An additional independent round of hierarchical clustering and consensus clustering with the NMF approach provided a validation for the classification. Kaplan-Meier analysis with the log rank test pointed to a non-significant difference in survival (p=0.071) but the likelihood of survival to 6 years was significantly different between the two groups (40.5% vs 81.8%, p=0.014, Z-test). Biological process categories characteristic for each subclass were identified statistically and up-regulation of cell-proliferation related genes was evident in the subclass with a poor prognosis. In the subclass with the better survival, genes involved in differentiated intracellular functions, such as the MAPKKK cascade, ceramide metabolism, or regulation of transcription, were up-regulated. Keywords: repeat sample
2009-04-01 | E-GEOD-2088 | biostudies-arrayexpress
Project description:Using non-negative matrix factorization to identify glioblastoma subtypes from NanoString gene expression data
2021-06-13 | GSE177549 | GEO
Project description:Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and validated by non-negative matrix factorization . BACKGROUND: Current clinical and histopathological criteria used to define lung squamous cell carcinomas (SCCs) are insufficient to predict clinical outcome. We attempted to make a clinically-useful classification based on gene expression profiling. METHODS: We used cDNA microarrays with 40386 elements to analyze the gene expression profiles of 48 surgically resected samples of lung SCC. 9 samples of lung adenocarcinoma and 30 of normal lung were also included to give a total of 87 samples analyzed. After gene filtering, the data were subjected to hierarchical clustering and consensus clustering with the non-negative matrix factorization (NMF) approach. FINDINGS: Initial analysis by hierarchical clustering allowed division of SCCs into two distinct subclasses. An additional independent round of hierarchical clustering and consensus clustering with the NMF approach provided a validation for the classification. Kaplan-Meier analysis with the log rank test pointed to a non-significant difference in survival (p=0.071) but the likelihood of survival to 6 years was significantly different between the two groups (40.5% vs 81.8%, p=0.014, Z-test). Biological process categories characteristic for each subclass were identified statistically and up-regulation of cell-proliferation related genes was evident in the subclass with a poor prognosis. In the subclass with the better survival, genes involved in differentiated intracellular functions, such as the MAPKKK cascade, ceramide metabolism, or regulation of transcription, were up-regulated. Keywords: repeat sample
2009-04-01 | GSE2088 | GEO
Project description:Methylation is closely involved in the development of various carcinomas. However, little datasets are available for small cell lung carcinoma (SCLC) due to the scarcity of fresh tumor samples. The aim of this study is to investigate the comprehensive genome-wide methylation profile of SCLC to predict the prognosis after surgical treatment. We investigated the high DNA methylated and low gene expression sites using 25 SCLC tumor tissues. First, we selected most differentially methylated CpG sites across the tumor tissues. Following hierarchical clustering (HC) and non-negative matrix factorization (NMF), gene ontology analysis was performed using DAVID software. Clustering of SCLC tumors led to the important identification of a CpG island methylator phenotype (CIMP) of SCLC, and showed that CIMP-high tumors had a significantly poorer prognosis (p = 0.001). Multivariate analysis revealed that postoperative chemotherapy, low neuroendocrine expression and the CIMP-low state were significantly good prognostic factors. Association analyses of methylation and gene expression provided 46 genes with significant correlation. Ontology studies to these genes showed that genes involved in extrinsic apoptosis pathway were suppressed, including TNFRSF1A, TNFRSF10A and TRADD, in CIMP-high tumors, prognosis of which was poorer. By comprehensive DNA methylation profiling, two distinct subgroups were identified to evoke a CIMP of SCLC as a useful marker for determination of treatment. Delineation of this phenotype may also be useful for the development of novel apoptosis-related chemotherapeutic agents for the treatment of an aggressive subtype of SCLC. Comprehensive genome-wide methylation analyses
2014-10-04 | E-GEOD-62021 | biostudies-arrayexpress
Project description:Clinical data from this cohort of patients, including hormone sensitive or castration resistant prostate cancer, overall survival, NMF subtypes, tumor TMB, prior treatment status, PD-L1 IC and TC scores from SP142 and SP263 as well as percentage of CD8 IHC at tumor center.
| EGAD00001008761 | EGA